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Abstract UK l l4  is a tumor antigen expressed by various 
malignant neoplasms. The complete amino acid sequence of 
UK l l4  purified from goat liver has been determined by 
automated Edman degradation of CNBr and endoproteinase 
Lys-C peptides. The protein contains 137 amino acid residues, 
which corresponds to a molecular mass of 14 229 Da. MALDI- 
TOF analysis resulted in a molecular weight of 14290, 
suggesting that the N-terminal Met residue is acetylated. 
Sequence comparison shows that UK l l4  from goat liver (1) 
has 77% identity with a previously described 23 kDa protein 
from rat liver (Levy-Favatier et al. (1993) Eur. J. Biochem. 212, 
665-673), (2) shares a very high degree of similarity with a 
family of prokaryotic and eukaryotic hypothetic proteins whose 
function have not yet been characterized, and (3) exhibits a 
significant similarity to a group of tumor-associated antigens 
which belongs to a superfamily of heat shock proteins, acting as 
possible targets for the host's antitumor immunity. 
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cused our attention on the 14 kDa protein. Bartorelli et al., 
using immunocytochemical studies [8], have demonstrated the 
presence of UK114 in various, adenocarcinoma type, human 
malignant neoplasms. The same authors located UK l l4  on 
the cell membrane of several human cancer cell lines. More- 
over, they showed that anti-UK114 antibodies induce cytoly- 
sis in vitro and cause a marked delay of tumor growth in vivo. 
These experiments uggest that human tumors expressing 
UK114 on the surface of the cell membrane may undergo 
antibody-mediated cytolysis. Thus, UK l l4  is thought to be 
the main significant component of UK101 with potential 
pharmacological ctivity. Preliminary structural results sug- 
gested that UK114 might be a protein not yet characterized 
[6]. In this paper we present he complete primary structure of 
UK114 as a preliminary step to investigation of its biological 
activity. 
2. Material and methods 
1. Introduction 
The presence and activity in neoplastic ells of different 
tumor-associated antigens has been widely demonstrated (for 
a review see [2]): nevertheless their molecular nature remains 
in many cases largely unknown. Bartorelli et al. [3,4] have 
recently described a new group of tumor-associated antigens, 
extracted from goat liver with perchloric acid and indicated as 
UK101. Policlonal antisera and monoclonal antibodies anti- 
UK101 react against 90% of human tumors tested, confirming 
the hypothesis that antigens very similar to the proteins con- 
tained in UK101 are expressed in neoplastic tissues. More- 
over, UK101 induces an in vivo antineoplastic effect, reducing 
in several cases the metastatic masses [4,5]. 
UK  101 contains three major proteins [6]: (1) a 10 kDa 
protein (UKl l0) ,  (2) a 14 kDa protein (UKl l4) ,  and (3) a 
50 kDa protein (UK150). The larger component, UK150, was 
shown to be a mannose-rich glycoprotein and did not exhibit 
any of the potential immunological nd antineoplastic proper- 
ties of UK101 fractions [6,7]. UK110 consists of a mixture of 
integer ubiquitin and its degradation products, derived from 
partial removal of C-terminal residues. However, ubiquitin 
alone does not produce any therapeutic effect. Thus we fo- 
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Abbreviations." CNBr, cyanogen bromide; MALDI-TOF, matrix- 
assisted laser desorption/ionization time of flight; TFA, trifluoroacetic 
acid; PVDF, polyvinylidene fluoride; AQC, 6-aminoquinolyl-N- 
hydroxysuccinimidyl carbarnate 
2.1. Materials 
Endoproteinase Lys-C was from Boehringer Mannheim. TFA, 6 N 
HC1 and CNBr were from Pierce Chemical Company. Immobilon-P 
membrane and AQC were from Millipore. All other reagents used 
were of the highest purity commercially available. 
2.2. Purification and structural characterization f UKl l 4 
Purification of UK114 from goat liver was performed as previously 
described [7]. The primary structure of the protein was determined 
after (1) in situ CNBr fragmentation f the native protein blotted on 
PVDF membrane as described in [9] and (2) CNBr fragmentation f 
UK114 in 70% formic acid [10] followed by reduction and alkylation 
of CNBr peptides with iodoacetamide and endoproteinase Lys-C di- 
gestion [11]. Peptides were purified by RP-HPLC as described by [10]. 
Amino acid sequence was determined using an Applied Biosystems 
Mod. 477/A pulse liquid-phase sequencer (Table 1, Fig. 3). 
2.3. Miscellaneous methods" 
Amino acid analysis was performed after gas-phase hydrolysis by 
pre-column derivatization with AQC [12], as previously described [13]. 
Molecular weight was determined either by SDS-PAGE or by 
MALDI-TOE mass spectrometry using a focus/LD-TOF spectrometer 
(VESTEC Instruments) and a saturated solution of sinapinic acid in 
0.1% TFA/acetonitrile (2: 1, v/v) as matrix. 
3. Results and discussion 
Approximately 1 5 nmol of native and carbamidomethyl- 
ated protein was subjected to automated Edman degradation 
but no phenylthiohydantoin derivative could be identified, 
indicating that the amino-terminal residue of the protein 
was blocked. Thus the amino acid sequence of UK114 had 
to be determined after characterization and sequence align- 
ment of the peptides obtained by CNBr fragmentation alone 
and CNBr fragmentation followed by endoproteinase Lys-C 
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Fig. 1. The primary structure of UKI14. The continuous line indi- 
cates the sequence derived from CNBr fragmentation f the protein. 
The dashed line indicates the sequence derived from the endopro- 
teinase Lys-C digestion. 
digestion. Fig. 1 summarizes the data used to determine the 
complete primary structure of UK114. The protein consists of 
137 amino acid residues, and the calculated molecular mass of 
14229 Da agrees with the value of 14290 determined by 
MALDI-TOF analysis. The 60 Da difference between theore- 
tically and experimentally determined masses could be ex- 
plained by the amino-acetylation f N-terminal residue of 
methionine. The amino acid composition deduced from the 
sequence agrees well with that determined experimentally 
(data not shown). It should be pointed out that in situ 
CNBr fragmentation failed to cleave the peptide bond be- 
tween Met I and Ser 2, allowing the unambiguous determina- 
tion of the sequence from Asp 1° to Leu s:~. 
The alignments between Gly :Es and Met :~9, Lys !~ and Gln ~s, 
Lys lit and Gly us were deduced from the similarity between 
UK114 and the closely related proteins hown in Fig. 2. 
A BLAST [14] search of UKI I4  with other proteins in 
EMBL/Genebank and SwissProt databases revealed a very 
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Fig. 2. Sequence alignment between the primary structure of UKII4 
and the sequence of other closely related proteins, the YER057C/ 
Y|L051C/Y5GF family and 23 kDa (A), the MHC-binding protein 
MBP-2 (B) and hsp90 (C). The identities are indicated in bold. Con- 
servative substitutions are indicated in italics. 
high degree of identity (77%) between UK114 and a rat per- 
chloric acid-soluble 23 kDa protein [1]. The latter was origin- 
ally described as a dimer of two identical 99 amino acid poly- 
peptides (starting from Met :~9 to Vall:~7). However, Oika 
(D49363, GeneBank) showed that the published sequence of 
the 23 kDa protein is partially incorrect, since insertion of a 
guanosine base at position 28 of the cDNA would results in a 
new open reading frame which codes for a 137 amino acid 
polypeptide. 
Furthermore, UK114 exhibits a very high degree of identity 
with a group of proteins belonging to the so-called YER057C/ 
YIL051C/Y5GF family. Fig. 2A shows the alignment between 
UKI I4  and the sequence of the two most similar proteins 
belonging to this family, the YABJ from Bacillus subtilis 
and the Y5GF from E. coli (58% and 52% identity, respec- 
tively). 
The functions of the proteins belonging to this family have 
not yet been characterized, but it is interesting to note that the 
sequence of UK114 is very well conserved uring evolution 
from prokaryotic to mammalian. 
Comparison of the amino acid sequence of UK114 with 
protein sequences in the NCBI Entrez database (Beauty algo- 
rithm [15]), revealed also a high degree of similarity between 
portions of UK114 and of two closely related MHC-binding 
proteins, MBP-1 and MBP-2, which belong to a family of 
transcription factors involved in the regulation of MHC class 
I gene expression [16] (Fig. 2B). However, such portions in 
MBP-I and MBP-2 do not belong to those regions which are 
suggested to be related to their functions. 
Finally, the region from residue 46 to residue 100 exhibits a 
significant (35%) similarity with a highly conserved region of 
human hsp90, as already reported by Levy-Favatier et al. [1] 
for the 23 kDa protein (Fig. 2C). Heat shock proteins (hsp) 
play several essential roles within the cell. In particular hsp90 
and hsp70 can elicit a tumor-specific mmunity [17,18]. Hsp 
peptides complexed with MHC class I molecules may be pre- 
sented to T cells [19]; hsp themselves may act as a presenting 
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Fig. 3. HPLC chromatography of UK114 following CNBr fragmen- 
tation and Lys-C digestion. Peak numbers refer to the alignment 
shown in the test. 
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Table 1 
Amino acid sequence of peptides obtained from in situ CNBr fragmentation f UK114 
tion (L1, etc.) and HPLC chromatography (see Fig. 3) 
(C2) or CNBr fragmentation followed by Lys-C diges- 
C2 C2 (cont.) LI L2 L3 
(pmol) (pmol) (pmol) (pmol) (pmol) 
l Asp 879 
2 Pro 746 
3 Ala 1112 
4 Ser 152 
5 Gly 692 
6 Gln 753 
7 Leu 252 
8 Val 486 
9 Pro 380 
10 Gly 527 
1 Gly 524 
12 Val 556 
13 Val 721 
14 Glu 214 
5 Glu 256 
16 Ala 590 
17 Lys 112 
18 Gln 361 
19 Ala 520 
20 Leu 510 
21 Thr 91 
22 Asn 120 
23 Ile 298 
24 Gly 326 
25 Glu 72 
26 Ile 284 
27 Leu 349 
28 Lys 108 
29 Ala 439 
30 Ala 380 
31 Gly 159 
32 (Cys) n.d. 
33 Asp 63 
34 Phe 219 
35 Thr 58 
136 Asn 78 
37 Val 284 
38 Val 319 
39 Lys 59 
40 Ala 398 
41 Thr 29 
42 Val 210 
43 Leu 194 
44 Leu 228 
1 Ser 52 
2 Glu 24 
3 Asn 15 
4 Ser 16 
5 Glu 17 
6 Glu 22 
7 Pro 39 
8 Val 34 
9 Gly 46 
10 Glu 22 
11 Ala 19 
12 Lys 6 
1 Ala 
2 Pro 
3 Ala 
4 Ala 
5 Ile 
6 Gly 
7 Pro 
8 Tyr 
9 Ser 
10 Gin 
11 Ala 
12 Val 
13 Leu 
14 Val 
15 Asp 
16 Arg 
17 Thr 
18 Ile 
19 Tyr 
20 Ile 
21 Ser 
22 Gly 
23 Gln 
24 Leu 
25 Gly 
26 (Met) 
258 
226 
177 
182 
160 
166 
153 
98 
45 
68 
90 
114 
65 
130 
1 Asp 89 
2 Pro 142 
3 Ala 207 
4 Ser 52 
5 Gly 292 
6 Gin 106 
7 Leu 161 
8 Val 200 
9 Pro 105 
10 Gly 238 
11 Gly 192 
12 Val 162 
13 Val 216 
14 Glu 30 
42 
90 
11 
35 15 Glu 
15 16 Ala 
32 17 Lys 
92 
40 
70 
30 
56 
28 
26 
26 
n.d. 
L4 L5 L6 L7 L8 
(pmol) (pmol) (pmol) (pmol) (pmol) 
1 Gin 178 
2 Tyr 218 
3 Phe 251 
4 Gin 154 
5 Ser 43 
6 Ser 43 
7 Phe 156 
8 Pro 69 
9 Ala 172 
10 Arg 34 
11 Ala 90 
12 Ala 100 
13 Tyr 58 
14 Gin 26 
15 Val 94 
16 Ala 76 
17 Ala 100 
18 Leu 68 
19 Pro 17 
20 Lys 5 
1 Gin 1161 
2 Ala 1050 
3 Leu 1022 
4 Thr 463 
5 Asn 520 
6 Ile 672 
7 Gly 613 
8 Glu 427 
9 Ile 509 
10 Leu 348 
1 Lys 36 
1 Ala 297 
2 Thr 79 
3 Val 260 
4 Leu 165 
5 Leu 185 
6 Ala 155 
7 Asp 91 
8 Ile 184 
9 Asn 37 
10 Asp 51 
11 Phe 114 
12 Ser 25 
13 Ala 72 
14 Val 163 
15 Asn 27 
16 Asp 19 
17 Val 114 
18 Tyr 32 
19 Lys 4 
1 Gly 424 
2 Gly 372 
3 Arg 100 
4 Val 296 
5 Glu 174 
6 lie 231 
7 Glu 159 
8 Ala 176 
9 ile 143 
10 Ala 109 
11 Val 150 
12 Gin 171 
13 Gly 132 
14 Pro 36 
15 Leu 63 
16 Thr 21 
17 Thr 58 
18 Ala 76 
19 Ser 27 
20 Val 11 
1 Ala 302 
2 Ala 361 
3 Gly 427 
4 CAM-Cys 2 
5 Asp 144 
6 Phe 225 
7 Thr 108 
8 Asn 170 
9 Val 166 
10 Val 234 
11 Lys 5 
Numbers following residues report the amount in pmol detected in each cycle, n.d., not detected; CAM-Cys, carbamidomethyl c steine. 
molecule, complexed with endogenously derived cellular pep- 
tides [20]. Furthermore, it has been demonstrated [21,22] that 
hsp are maintained at low levels in normal cells and are con- 
fined inside the cytoplasm; the stress induces an unusual ex- 
pression of these proteins and a targeting both in cell com- 
partments and on the cell surface. 
On the basis of sequence similarities and immunocytochem- 
ical studies we can speculate about the putative role of 
UK114; as previously described for hsp, UK114 is expressed 
on the surface of the cell as an effect of stress induced by the 
neoplastic transformation and recognition of UK114 by anti- 
UK114 antibodies induces an antibody-mediated cytolysis of 
the tumoral cell. This proposed mechanism could be consist- 
ent with the immunological properties and localization of 
UK l14  described in [8]. Although the regulation of UK l l4  
expression and correlation with the neoplastic transformation 
of the cell have not been investigated in detail, both the pri- 
mary structure of UK114 and expression of this protein as a 
cancer-dependent phenomenon confirms the hypothesis that 
UK114 belongs to a group of tumor-associated antigens act- 
ing as a possible target for the host's antitumor immunity. 
Nevertheless, it is not clear if the antigenity of UK114 derives 
from the protein per se or, alternatively, from associated pep- 
tides, this hypothesis suggesting a role as molecular chaperon 
of antigenic peptides, as described for hsp90 [17,18]. 
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